Improving outcome in treatment of diabetics with ST elevation myocardial infarction: insights from the GUSTO trials  by Gurm, Hitinder S. et al.
5 
"C 
t~ 
E 
292A ABSTRACTS- Myocardial Ischemia and Infarction 
diameter of 12 smooth and 10 complex coronary stanoses and their adjacent reference ( 
R ) segment was measerad by quantitative angiography. 
Results: LA 50 ~mol/min dilated smooth stenoses (6.4+/-1.4%) and complex stenoses 
(7.3+/-3.2%). LA 150 I~mol/min significantly dilated smooth (7.3+/-2.9%) and complex 
stenoses (13.7+/-2.5%, p<0.05 vs smooth stanoses). No significant difference was found 
in R segment for smooth and complex stenoses in response to 50 pmol/min (4.5+/-1.4% 
and 6.3+/-2.9% respectively) and to 150 iJmol/min (10.5+/-2.2% vs 10.4+/-2.4%). GTN 
significantly dilated smooth (14.9+/-3.4%) and complex stanoses (19.4+/-2.3%). There 
was a significant correlation between stenosis severity and LA induced dilation (r=0.56, 
p<0.001). 
Conclusion: In patients with CAD, complex coronary stanoses dilate significantly more 
than smooth stanoses after LA administration. This finding is consistent with partial defi- 
ciency of the substrate for nitric oxide synthesis at the site of complex stenoses. The pro- 
vision of LA significantly enhances nitric oxide activity at the site of complex severe 
stenoses. 
1051-48 Selective Serotonin 5HT2A Receptor Inhibition 
Attenuates Myocardial lachemia Through the Increase 
in Nitric Oxide Production: The Alternative Role of 
5HTIB Receptor 
Shoii Sanada. Masafumi Kitakaze, Koichi Node, Hiroshi Asanuma, Hisekazu Ogita, Seiji 
Takashima, Masanori Asakura, Tetsuo Minamino, Masatsugu Hod, Osaka University 
Graduate School of Medicine, Suita, Japan, National Cardiovascular Center, Suita, 
Japan. 
Background: Serotonin is released during myocardial ischemia and activates both 
5HT1B/2B and 5HT2A receptors. The former activation increases nitric oxide (NO) produc- 
tion, and the latter constricts coronary artery. If 5HT2A receptors are blocked during myo- 
cardial ischemia, relative activation of 5HT1B/2 B receptors may enhance NO production 
and increase coronary blood flow (CBF). Therefore, we tested this idea using a selective 
serotonin 5HT2A receptor inhibitor, sarpogralate hydrochloride, in ischemic canine heart. 
Methods: After hemodynamic stabilization, blood flow of the left anterior descending cor- 
onary artery (LAD) was reduced to one-third of the baseline with low constant coronary 
perfusion pressure (CPP: 40.2±3.4mmHg). Thereafter, sarpogrelate (4.66 mg/CBF (L/ 
rain)) was infused for 15 min into the LAD with or without an intracoronary infusion of L- 
NAME (an inhibitor of NO synthesis; 10 mg/CBF (IJmin)) or GR55562 (a selective 5HTIB 
blocker; 0.457 mg/CBF (LJmin)) (the Sarpogralata+L-NAME group, the Sarpogrelate 
group and the Sarpogrelate+GR55562 group, respectively) under constant CPP. 
Results: There were no significant differences in CBF and CPP at the baseline condition 
between two groups. Fifteen min after the Sarpogralate administration, CBF increased 
from 34.0±4.0 to 44.5±4.4 ml/1OOg myocardium/min (n=10, p<0.01), greater (p<0.05) 
than that in the Sarpogrelate+L-NAME group (from 31.1±3.5 to 31.6±2.7 ml/100g myo- 
cardiurn/min, n=9, N.S.). 
Conclusion: We conclude that a selective serotonin 5HT2A receptor blocker, sarpogre- 
late hydrochloride, increases coronary blood flow during ischemia via nitric oxide-depen- 
dent mechanism in canine hearts. Sarpogralate hydrochloride can be beneficial for the 
treatment of ischemic heart disease. 
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1074-31 Left  Ventr icu lar  Fi l l ing and Remodeling After Myocardial 
Infarction: Results From the GISSI-3 Echo Substudy 
Pier L. Temeorelli. Pantaleo Giannuzzi, Francesco Gentile, Donata Lucci, Aide P. 
Maggioni, Gian Luigi Nicolosi, Sa/vatore Maugeri Foundation, Veruno, Italy, Centre Studi 
ANMCO, Firenze, Italy. 
Background. We sought to determine the relation between LV filling pattern and remodel- 
ing in a large cohort of post-AMI patients (pts). 
Methods. Doppler mitral profile, end-diastolic (EDVi) and end-systolic (ESVi) volume 
index, ejection fraction (EF) and extent of wall motion abnormalities (%WMA) were eval- 
uated in 571 pts enrolled in the GISSI-3 Echo substudy, with echo-Doppler recordings at 
24-48 hours (baseline), pre-discharge, and 6 months after uncomplicated AMI. On trans- 
mitral pattern, peak early (El and late (A) velocity, their ratio (E/A), and early deceleration 
time (DT) were considered. According to baseline DT, pts were assigned to group 1, with 
DT <130 ms (n = 147), and group 2, with DT >130 ms (n = 424). 
Results. Pts in group 1 had greater ESVi (p<0.05) and %WMA (p<0.01), and ]ower EF 
(p<0.008) than those in group 2; moreover, despite a greater increase in DT (from 116 to 
165 ms, group 1; from 173 to 186 ms, group 2, p< 0.001), they showed a more severe 
dilation after 6 months (EDVi: from 61 to 94 mVm2 in group 1; from 78 to 82 ml/m2 in 
group 2, p<0.00t; ESVi: from 46 to 55 ml/m2 in group 1; from 41 to 43 ml/m2 in group 2, 
p<0.001) together with an impairment in EF (from 44 to 42%, group 1; from 48 to 46% 
group 2, p< 0.008) and a lesser recovery of %WMA (from 31 to 28 group 1; from 23 to 17 
group 2, p<0.01). Among the 147 group 1 pts, those with pre-discharge persistent DT 
<130 ms (n = 56) showed at 5 months a greater EDVi and ESVi enlargement (p<0.001), 
and a greater impairment in EF (p<0.009) compared to those (n = 91) with significant pro- 
longation of DT (>130 ms). At multivariate analysis, baseline DT <130 ms (OR: 2.38), 
EDVi (OR: 0.96) and %WMA (OR: 1.02) were predictors of >5% dilation at 6 months; 
moreover, when changes in %WMA, EF and DT from baseline to pre-discharge were 
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included in the analysis, baseline %WMA (OR: 1.02) and EDVi (OR: 0.95), together with 
pre-discharge persistent short (<130 ms) DT (OR: 3.06), predicted severe (>20%) late LV 
dilation. 
Conclusion. LV dilation occurs even in uncomplicated MI, in spite of significant recovery 
of %WMA and improvement in LV filling. A short (<130 ms) baseline DT which persists at 
pre-discharge allows identification of pts more compromised and at high risk for progres- 
sive late LV dilation. 
1074-32 Benef ic ia l  Effect of  Revascular izsUon in E lder ly Pat ients  
With Card iogen ic  Shock 
Aaron Kuoetmass. Sai Sadanandan, Lynn G. Tarkington, Salvatora L Battaglia, Apdl W. 
Simon, Steven D. Culler, Edmund R. Becker, Emory Universi~ Atlanta, Georgia, 
University of Oklahoma, Oklahoma City, Oklahoma. 
Background: Previous studies of cardiogenic shock (CS) patients have shown patients 
_> 75 y/o (older CS) do not receive benefit from coronary revascularization. This retro- 
spective study assesses the impact of various revascularization treatment strategies on 
in-hospital survival rates among CS patients in a community setting, after adjusting for 
differences in a patient's gender and 27 co-morbid conditions, 
Method: The sample for this study, 5,030 consecutive CS patients who had a hospital- 
ization with a primary diagnosis of acute MI, was selected from a dataset on all patients 
discharged from HCA Hospitals for the period January 1998 through March 2001. Logis- 
tic regression analysis, estimated separately for younger (n=2525) and old (n=2505) CS 
patients, was used to determine if the observed revascularization treatment strategy 
(thrombolytic only, PCI only, CABG only, or PCI and CABG) improved hospital survival. 
Results: The table indicates that elderly CS patients undergoing revescularization treat- 
ment are between 1.73 times (thrombolytics only) and 2.49 times (CABG only) more 
likely to survive an acute MI hospitalization than elderly CS patient receiving no treat- 
ment. Younger CS patients received even greater benefit from each treatment strategy. 
Conclusions: Reperfusion with thrombolytics or mechanical revascularization signifi- 
cantly impoves survival in older, as well as younger AMt patients with CS. An aggressive 
revascularization strategy should be considered in elderly CS patients. 
Risk Adjusted Odds Ratios for Survival by Treatment Strategy Relative to No 
Treatment 
Age < 75 Age 75 or Greater 
Thrombotytics Only 1.93 (p=0.007) 1.73 (p=0.033) 
PCI Only 2.39 (p<O.O01) 2.06 (p<0.001) 
CABG Only 2.61 (p<O.001) 2.49 (p<O.001) 
PCI and CABG 3.01 (p<O.001) 2.47 (p=O.O06) 
1074-33 Improving Outcome in Treatment of Diabet ics With ST 
Elevation Myocardial Infarction: Insights From the 
GUSTO Trials 
Hitinder S. G~rm, WH Wilson Tang, David Lee, Gang Jia, A Michael Lincoff, Eric J. Topoi, 
Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: Diabetics with acute ST-segment elevation myocardial infarction (MI) have 
a worse outcome compared to non-diabetics. Higher risk patients are more likely to ben- 
efit from advances in medical therapy. Methods: We analyzed the diabetic patients 
enrolled in GUSTO I, III and V trials to define the trends in use of adjuvant therapies and 
in short-term outcome. We excluded patients from countries that were not represented in 
all the three trials. Results: The GUSTO I,III and V trials enrolled 9200 diabetics and 
52,509 non-diabetics. Compared with non-diabetics, diabetics were more likely to be 
older (mean age 63.98 ± 10.68 vs. 60.77 ± 12.19, P < 0.001), female (35.1% vs. 24.3%, 
P <0.001), and more likely to have previous history of CHF, CABG, MI, previous PTCA, 
hypertension and greater body weight. Diabetics were at a greater risk of in-hospital 
death (9.5% vs. 5.5% %, P <0.001), and 30 day mortality (10.4% vs 6.0, P < 0.001 ). Con- 
clusions: Compared to non-diabetics, diabetics continue to have a worse presentation 
and a worse outcome with myocardial infarction. Compared to patients enrolled in 
GUSTO I and III, patients enrolled in GUSTO V were more likely to receive beta blockers 
and angiotensin converting enzyme inhibitors and to have a better 30 day survival. This 
improved outcome is predominantly due to an improved survival of patients in Killip class 
I and II. 
Diabetic subset GUSTO I GUSTO Ill GUSTO V P value 
Number 14.5% 15.7% 16.4% 0.001 
(Diabetic/Total) (5376/37110) (1886/11996) (1938/12603) 
30 day mortality 10.7% 10.9% 8.9% 0.061 
30 day-mortality (Killip I and II) 9.3% 9.6% 7.5% 0.04 
(474/5 f 19) (173/1802) (140/1870) 
30 day mortality (Killip lit and IV) 44.5% 44.1% 50.0% 0.722 
(89/200) (26/59) (32/64) 
ACE inhibitor use 28.9% 54.9% 67.3% <0.001 
Beta blocker use 75.1% 75.7% 83.5% <0.001 
Aspirin use 98.1% 98.6% 93.2% <0.001 
